A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)

Magnevist - Pharmacology:

Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. MR images are based primarily on proton density and proton relaxation dynamics. MR instruments are sensitive to two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). Paramagnetic agents contain one or more unpaired electrons that enhance the T1 and T2 relaxation rates of protons in their molecular environment. The proton relaxation effect (PRE) of an unpaired electron is 700 times stronger than that of a proton itself. In MRI, visualization of normal and pathological brain tissue depends in part on variations in the radio frequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadopentetate dimeglumine shortens the T1 and T2 relaxation times in tissues where it accumulates. In the central nervous system (CNS), gadopentetate dimeglumine enhances visualization of normal tissues that lack a blood-brain barrier, such as the pituitary gland and the meninges. Magnevist does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in CNS lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadopentetate dimeglumine in lesions such as neoplasms, abscesses, and subacute infarcts. Outside the CNS, gadopentetate dimeglumine rapidly reaches equilibrium in the interstitial compartment and enhances signal in all tissues as a function of delivery and size of the interstitial compartment.

Magnevist mini report

Magnevist NDA
NDA - A product marketed under an approved New Drug Application
Magnevist global name
gadopentetate dimeglumine
Magnevist global name
Gadopentetate dimeglumine
Start - Stop data
Start - Stop data
not occurred

Magnevist for patients

Patients scheduled to receive MAGNEVIST® Injection should be instructed to inform their physician if the patient:

1. Is pregnant or breast feeding.

2. Has any blood disorders; i. e., anemia, hemoglobinopathies, or diseases that affect red blood cells.

3. Has a history of renal or hepatic disease, seizure, asthma or allergic respiratory disorders.

Magnevist Interactions

No information provided.

Magnevist Contraindications


Magnevist tags categories:

Generic name, Overdose, Half Life Magnevist, Food Interactions, Chemical, etc..

Magnevist see also FDA report